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ABSTRACT: We present a novel solid-phase based 45Ti radiolabeling methodology and the implementation of 45Ti-PET in 
titanium-based antineoplastics using the showcase compound [45Ti](salan)Ti(dipic). This development is intended to 
allow elucidation of the biodistribution and pharmacokinetics of promising new Ti-based therapeutics. 
■   INTRODUCTION 
The success of Pt-based anticancer drugs has spurred 
intense research activity directed towards development of 
new metal-based antitumor agents1–3. Among few others, 
Ti has emerged as a promising antineoplastic metal4. 
Following encouraging preclinical results the first genera-
tion of anticancer drugs, Cp2TiCl2 and budotitane entered 
clinical trials but eventually failed to translate due to poor 
solubility and high hydrolytic instability of titanium4,5. 
However, recent advances in titanium-stabilizing ligands 
have led to a new class of cytotoxic Ti-based antineoplas-
tics5. Prominently, introduction of the ligand salan, a 
diamine bisphenalato compound, conferred excellent 
hydrolytic stability to Ti(IV) alkoxide complexes, as pre-
sented by Tshuva and co-workers (Chart 1, 1)6–13. Many of 
these compounds also demonstrated micro- and submi-
cromolar antiproliferative activity against HT29 and 
OVCAR-1 cancer cell lines in vitro. In line with developed 
structure-activity relationships14, by substituting the ter-
minal alkoxide ligands (OR in Chart 1, 1) with dipicolinic 
acid, Immel et al. obtained a hydrolytically and chroma-
tographically stable complex, (salan)Ti(dipic) (Chart 1, 
2)14. 2 exhibited cytotoxicity against HeLa S3 and Hep G2 
cell lines: a finding that prompted in vivo therapeutic 
tests in tumor-bearing mice14. 
Generally, the transition from in vitro cell cultures to in 
vivo application raises important considerations about the 
biological fate of a potential pharmaceutical. Positron 
emission tomography (PET) addresses these concerns by 
non-invasively determining the concentrations of radio-
labeled compounds as they distribute in vivo16. The simi-
lar technique of single photon computed tomography 
(SPECT) has recently been employed to clinically deter-
mine the distribution of [195mPt]cisplatin in an effort to 
relate the pharmacokinetics to treatment efficacy17.  Turn-
ing to Ti-based antineoplastics, implementation of PET 
and radiotracing early in preclinical development could 
aid in determining the mechanism of action, and evaluate 
dosing and drug formulation. In the present case PET is 
made possible by the titanium isotope 45Ti. 
 
Chart 1, Ti-based antineoplastic agents R=alkyl, aryl, 
R’=alkyl, halogen.  
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Scheme 1, Radiosynthesis of [45Ti](salan)Ti(dipic), [45Ti]2 on Hypogel 200 resin 
Amongst positron emitting radionuclides, 45Ti is highly 
desirable for biomedical application due to its decay 
characteristics: an 85% positron branch, low beta end-
point energy (1.04 MeV), 3.1 h half-life, and negligible 
secondary radiation18. Further, it is produced in high-yield 
by transmutation of naturally monoisotopic scandium via 
low energy proton irradiation19. Despite the promising 
physical characteristics, 45Ti radiochemistry is currently 
underdeveloped due to the hydrolytic instability of Ti(IV) 
in aqueous environments. While the titanium citrate 
complex is mildly stable20, previous radiochemical appli-
cation of [45Ti]titanium citrate by Ishiwata et al21 and 
Vāvere et al22,23 ended with partially hydrolyzed titanyl-
based complexes: precluding its use as an organometallic 
precursor.  
In order to bring the utility of 45Ti into the new salan-
based antineoplastic complexes we sought a method of 
45Ti recovery and chemical-activation on solid-phase. We 
hypothesized that a diol-functionalized resin would trap 
45Ti as a titanium diolate forming a resin-bound substrate 
structurally similar to Ti(i-PrO)4 used for the synthesis of 
1 and 2 (Scheme 1). 
In this preliminary report we present a novel solid phase-
based 45Ti recovery and radiolabeling methodology which 
potentially allows access to the wealth of organotitanium 
chemistry. This methodology is showcased by automated 
solid-phase radiosynthesis of antineoplastic 
[45Ti](salan)Ti(dipic), [45Ti]2, and its PET imaging and ex 
vivo evaluation in HT-29 colorectal tumor-bearing mice. 
■   RESULTS AND DISCUSSION 
Overall, the solid phase protocol allowed for efficient 
extraction of 45Ti from the Sc matrix and a flexible intro-
duction of multiple ligands, the excess of which could be 
removed by simple cartridge purification.45Ti, produced 
by the 45Sc(p,n)45Ti nuclear reaction in a cyclotron, was 
efficiently isolated from bulk scandium and hydrochloric 
acid solution on a column packed with HypoGel 200, a 
PEG-functionalized polystyrene-based symmetrical 1,3 
diol, with 93 ± 3% recovery (n = 6). Although the exact 
form of Ti(IV) in conc. HCl is not known, a line of exper-
imental evidence suggest [Ti(OH)2(H2O)4]Cl2 as a likely 
species24 (Scheme 1). Only traces of scandium were re-
tained on the column. This result agreed well with the 
measured distribution constants of Ti and Sc, where KTi = 
91.4 ± 10.5 mL/mg and KSc = 6.8 ± 1.4 mL/mg. With 
45Ti 
trapped on solid phase presumably as titanium diolate 
(Scheme 1, 3), the stage was set for introduction of salan 
and dipic.  
Preliminary experiments with non-radiolabeled materials 
revealed that salan and 2 had very similar retention on 
silica in our TLC system.  To ensure chemical purity of 
the desired [45Ti]2 the introduction of salan and dipic 
were performed sequentially. An on-column reaction of 
resin-bound 45Ti with salan occurred by a slow passage of 
the ligand through the resin (Scheme 1, 4). Unreacted 
salan was removed from the column by washing the resin 
with pyridine. These two steps combined were accompa-
nied by a 2-7% (n = 3) loss of radioactivity from the col-
umn. In the final step dipic was introduced. A control 
experiment performed under homogeneous conditions 
with non-radioactive (salan)Ti(i-PrO)2 and dipic showed 
that elevated temperature was required for formation of 
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2. Accordingly, dipic was introduced by recirculation of 
dipic in pyridine solution through the column at 100 oC. 
25-35% (n = 3) of the 45Ti was removed from the column 
at this step, of which 47-60% (n = 3) was present as 
[45Ti]2, and the rest as unidentified [45Ti]Ti-containing 
species having high affinity for silica. The resulting [45Ti]2 
was purified by passing the solution through a silica car-
tridge, dilution with NH4Cl(aq) and trapping [
45Ti]2  on the 
Sep-Pak C18 cartridge. The product was released from the 
C18 cartridge by elution with ethanol with an overall 15 ± 
4 % (n = 5) decay-corrected radiochemical yield (RCY) 
and 98% radiochemical purity (RCP) as evidenced by the 
HPLC/radio-HPLC and TLC/radio-TLC analysis (see ESI). 
ICP-OES analysis showed the specific activity of [45Ti]2 to 
be 10.7 MBq/nmol at the end of purification, and contain-
ing only 1.4 pmol of scandium per MBq. 
In order to investigate the in vivo behavior of 2, three 
different formulations of [45Ti]2 were created. In order to 
study the dynamic biodistribution and blood-clearance 
kinetics of 2, a formulation suitable for intravenous injec-
tion was made without carrier in saline containing 1% 
(w/v) Tween 20 and 10 mM HEPES buffer (pH 7.4): ‘no-
carrier-added intravenous’ (ncaiv). To match the reported 
conditions of Immel et al.: i.e. an intraperitoneal injection 
of [45Ti]2 with 112 µg non-radiolabeled 2, dissolved in 
DMSO, the second formulation was prepared. In our 
hands, this concentration of 2 was only achievable in neat 
DMSO. This formulation is referred to as ‘carrier-added 
intraperitoneal’ (caip). In order to identify any saturation 
behavior of 2, a third formulation was made in DMSO 
without added carrier, herein: ‘no-carrier-added intraperi-
toneal’ (ncaip).  
  
Figure 1, Dynamic PET time-activity-curve of the blood, liver 
and tumor ROI following ncaiv injection of [
45
Ti]2. The blood 
clearance was very rapid and followed a mono-exponential 
decay between 1 and 30 min post-injection with a half-time 
of 1.7 min, and baseline of 3.3 %ID/g. Points represent mean 
and error bars SEM (n=3). 
Imaging and biodistribution studies were carried out with 
NMRI nude mice bearing dual-flank HT-29 colorectal 
adenocarcinoma xenograft tumors. For the ncaiv injec-
tion, dynamic PET data were obtained for 30 minutes 
followed by static scans 3 and 7 hours after injection. The 
blood clearance rate was determined by quantifying a 
region of interest (ROI) over the heart and is illustrated in 
Figure 1, where a rapid 1.7 min half-time was observed 
between 1 and 30 minutes post injection. This demon-
strates that the circulation time of 2 is extremely short. 
The dynamic biodistribution is further demonstrated in a 
series of PET images, each corresponding to specific time 
point after ncaiv injection in Figure 2 (n=3). One can see 
that from the bloodstream the radioactivity has relocated 
to the liver, then to the gall bladder, and then to the in-
testines, showing distinctive hepatobiliary excretion pat-
tern, with almost no renal clearance (see also the video, 
ESI). Expressed as the percentage of the injected dose per 
gram tissue (%ID/g), the tumor accumulation never ex-
ceeded 1 %ID/g. To ascertain the degree of metabolic 
transformation [45Ti]2 underwent while still in the blood-
stream a blood sample was taken 10 minutes post iv injec-
tion. The sample was mixed with ethanol, centrifuged and 
the supernatant was analyzed by TLC/radio-TLC. All 
soluble radioactivity co-eluted with 2, indicating that it 
was present as chemically unmodified [45Ti]2. Overall, 
61% of the radioactivity was present in the supernatant, 
and the rest was tightly bound to the pellet.  
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Figure 2, Representative PET/CT images following iv injec-
tion of 1.6 MBq [
45
Ti]2, ncaiv, at various time points after 
injection. The arrows point at the ROI corresponding to: red 
– heart/blood; orange – liver; blue – gall bladder; pink – 
cecum; green: colon / feces.   
After ncaiv PET the animals were sacrificed and ex vivo 
biodistribution studies were performed (Figure 3,bottom). 
Significant activity was found in the liver, and intestines, 
confirming the PET data, and also, in the lungs and the 
spleen. The tumor accumulation was ~0.4 %ID/g. Next, 
we turned to the ncaip injections, followed by 3 and 7 h ex 
vivo biodistribution studies (Figure 3, top, n=3).  Both 
time points showed similar distribution as the bulk of the 
complex accumulated in the liver, gall bladder and intes-
tines. The highest tumor uptake was 0.5 ± 0.03 %ID/g at 3 
hours. To some degree the route of administration did 
influence relative biodistribution: the ncaiv showed in-
creased absorption of activity in lungs and blood, and 
reverse pancreas/spleen ratio compared to the ncaip for-
mulation. The high value in the intestines at 3 h (ncaip) 
shows the accumulation in this organ before fecal excre-
tion is responsible for the lower values observed at 7 h. At 
3 h post ncaip injection, blood, liver and gall bladder were 
each homogenized, mixed with ethanol and centrifuged. 
The supernatants were separated and the radioactivities 
measured at: gall bladder 88.3 ± 1.4%, liver 31.9 ± 16.3%, 
blood 13.7 ± 3.3% (supernatant + pellets = 100%, n = 3). 
The TLC/radio-TLC analyses performed on the superna-
tants of the liver and gall bladder (but not blood, due to 
low amount of radioactivity) showed that  less than 1% of  
[45Ti]2  remained intact, while the rest of the radioactivity 
had no mobility on silica (compare to Rf=0.57 for [
45Ti]2). 
Therefore, it appears that after 3 hours, most of the radio-
activity in the blood has been metabolized and/or became 
associated with insoluble substances. No further attempts 
at structural identification of metabolites were made. 
Finally, to match the conditions of Immel et al., the ncaip 
formulation was extended with caip. The PET was gener-
ally consistent with ncaiv PET described above (see ESI). 
However, the 8 h ex vivo studies using combined caip and 
ncaip allowed the concentration of 2 to be calculated in 
the tumor volume, as shown in Table 1. In the case of 
ncaip, on average 113 µg of 2 was injected, leading to a 
concentration of 257 pmol/g. When no carrier was added, 
the percentage of injected dose was similar to the caip 
case (see ESI), suggesting that for the doses given, no 
saturation effects were observed in the clearance. 
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Figure 3, Ex vivo organ biodistribution data from ncaip (top) 
and ncaiv (bottom) injections, n=3.  
Due to the 3 hour half-life of 45Ti, and the low tumor ac-
cumulation, it was impossible to determine the long-term 
kinetics of the compound. It is reasonable that during the 
month-long treatment course used by Immel et al. that 
the doses were additive, leading to the observed anti-
tumor effect.  
The data above also suggest that chemical modifications 
to make the complex more hydrophilic, and thereby in-
crease circulation time, or targeted drug delivery may 
improve the therapeutic value in vivo. 
Table 1, Results of the 8h ex-vivo biodistribution as 
pertain to the tumor tissue.  
 Injected 2 
(µg) 
Tumor uptake 
(%ID/g) 
Tumor conc. 
(pmol/g) 
ncaip 1.2 ± 0.1 0.18 ± 0.02 3.8 ± 0.5 
caip 113 ± 6 0.13 ± 0.01 257 ± 24 
 
■   CONCLUSION 
In conclusion, we reported an automated solid-phase 
radiosynthesis of [45Ti]2 and its PET and ex vivo evalua-
tion in a HT-29 colorectal tumor bearing mice. [45Ti]2 was 
found to metabolize  in the liver and to show fast hepato-
biliary excretion pattern, with almost no renal clearance.  
We expect the synthetic methodology to be applicable to 
a broad range of supporting and terminal ligands. It is our 
hope that this advance will allow elucidation of the in 
vivo behavior of promising titanium compounds and 
become a useful tool for accelerating clinical translation. 
Ultimately, if found, a Ti/45Ti-based anticancer agent with 
fast and significant tumor uptake would combine chemo-
therapeutic effect with diagnostic and molecular imaging 
features, ushering the Ti-based metallodrugs into the 
growing field of theranostics. 
■   EXPERIMENTAL SECTION  
45Ti was produced by 10-20 µA proton irradiation of 20-60 
mg scandium foil at approximately 13 MeV by a GE PET-
trace (after degradation from the nominal 16 MeV extrac-
tion energy by 500 µm thick aluminum). During irradia-
tion the scandium was thermally stabilized by contact to 
a water-cooled silver plate. The 45Ti-loaded foils were 
dissolved in 2-4 mL 4 M HCl, and the resulting solution 
was passed through a 0.45 µm Whatman syringe filter, 
and dried under argon flow at 120-140 oC. The residue was 
re-dissolved in 37% HCl to a scandium concentration of 
roughly 20 mg/mL, of which 1 mL was passed over 300 mg 
Hypogel 200 1,3 diol resin in an 8 mm ID column with 
polyethylene frits.  The resin had been rinsed and pre-
equilibrated with 37% HCl for at least 20 min before ap-
plication of the radioactive solution, and was kept wet 
with HCl. Flow was slow and governed by gravity, where 
typically 1 mL passed through the column in 2-3 minutes. 
45Ti was retained on the column and scandium passed 
through. After washing with an additional 3-5 mL of HCl, 
the column was dried by argon flow for 30 seconds. 
(salan)Ti(dipic) was synthesized as described in the litera-
ture15 and its NMR properties (1H, 13C) were in full agree-
ment with the reported data. Thin-layer chromatography 
(TLC) was run on pre-coated plates of silica gel 60, F254 
(Merck), eluent: ethylacetate-chloroform (1/1). Radio-TLC 
was performed with a Raytest MiniGita TLC scanner and 
Cyclone Plus Phosphor Imager(PerkinElmer).  
Radiosynthesis was performed on a custom-made robotic 
synthesizer. The HypoGel 200 1,3-diol resin (300 mg) 
containing 1-4 GBq of 45Ti obtained in the previous step 
was washed with acetonitrile (3.0 mL, 3.0 mL/min) to 
remove the residue of HCl from the column. A solution of 
salan in pyridine was then passed through the column 
(120 mg in 3.0 mL, 1.3 mL/min). The resin was then 
washed with pyridine (5.0 mL, 3.0 mL/min) to remove 
residual salan, and a solution of dipic in pyridine (35 mg 
in 4.0 mL) was recirculated through the column for 15 
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min keeping the temperature of the recirculating solution 
at 100 oC. Upon reaction with dipic [45Ti]2 entered the 
liquid phase. The resulting solution containing a mixture 
of [45Ti]2 and dipic in pyridine was passed through a Sep-
Pak Silica Plus cartridge and into 5% (w/v) aqueous am-
monium chloride (45 mL). The resulting aqueous mixture 
was passed through a Sep-Pak C18 Plus cartridge, and the 
cartridge was washed with water (10 mL). The product 
was then eluted in ethanol (3.0 mL), yielding [45Ti]2. After 
removal of samples for quality control experiments, the 
ethanol solution containing [45Ti]2 was taken to dryness 
with helium flow at 60˚C in preparation for in vivo for-
mulation. 
In the first experiment, three mice received 150 µL injec-
tions of ncaiv via the lateral tail vein (1.6 ± 0.18 MBq). 
After intravenous administration of ncaiv, PET acquisi-
tions were performed for the first 30 minutes (dynamic 
acquisition) and then 2x12 minutes at 3 and 7 hours after 
injection. All PET acquisitions were followed by CT imag-
ing.  In the second experiments, six mice received 50 µL 
ncaip (1.2 ±0.1 MBq). In the final experiment, four mice 
received 50 µL intraperitoneal injections of ncaip (14.4 
±0.9 MBq) and another four mice received 50 µL intraper-
itoneal injections of caip (13.0 ±0.7 MBq). For the intra-
peritoneal injections in the last experiment, PET acquisi-
tions were performed for 3, 6 and 10 minutes at 1, 3 and 7 
hours (respectively) after administration of ncaip or caip 
[45Ti]2. Ex vivo biodistribution was performed 3 and 7 
hours after injection of ncaip [45Ti]2 in the second exper-
iment and 8 h after injection in the last experiment. 
Region of interest (ROI) analysis was applied on the dy-
namic PET data to estimate the blood clearance of [45Ti]2 
injected intravenously (ncaiv). ROIs were drawn over the 
heart to estimate the activity in the blood pool. The time 
activity curve was fitted with a single exponential func-
tion to estimate the blood clearance halftime (Graphpad 
Prism 6.0).  
Animals were sacrificed after the last imaging time-point 
and their organs excised, weighed, and counted in a 
gamma well counter (Wizard2, PerkinElmer) for conven-
tional ex-vivo biodistribution. 
■   ASSOCIATED CONTENT 
*S Supporting Information contains general infor-
mation, Ti/Sc distribution constants, description of au-
tomation, quality control, formulation, animals and cell 
lines description. This material is available free of charge 
via the Internet at http://pubs.acs.org. 
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■   ABBREVIATIONS USED 
salan, 6,6'-((ethane-1,2-diylbis (methylazanediyl)) 
bis(methylene)) bis(2,4- dimethylphenol); dipic, pyridine-
2,6-dicarboxylic acid; ICP-OES, inductively coupled plas-
ma atomic emission spectroscopy; HT29, human colorec-
tal adenocarcinoma; OVCAR-1, human ovarian epithelial 
carcinoma; HeLa, human cervical adenocarcinoma; Hep 
G2, hepatocyte carcinoma; SPE, solid phase extraction; 
ROI, region of interest; caip, carrier-added intraperitone-
al; ncaip, non-carrier-added intraperitoneal; CT, comput-
ed tomography; %ID percent injected dose. 
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